Related Experiment Videos
Surgery for metastatic renal cell cancer
Shomik Sengupta1, Bradley C Leibovich, Michael L Blute
1Department of Urology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
World Journal of Urology
|July 1, 2005
Summary
Surgery for metastatic renal cell carcinoma (RCC) can palliate symptoms or improve survival in select cases. Combining cytoreductive surgery with immunotherapy shows promise, but optimal timing and role require further study.
Area of Science:
- Oncology
- Surgical Oncology
- Immunotherapy
Background:
- Metastatic renal cell carcinoma (RCC) management has evolved from primarily surgical to incorporating systemic immunotherapy.
- Understanding the evolving role of surgery in conjunction with immunotherapy is crucial for optimizing patient outcomes.
Purpose of the Study:
- To review the current indications and scope of surgical treatment for patients with metastatic renal cell carcinoma (mRCC).
- To evaluate the potential benefits and limitations of surgical interventions in the context of modern systemic therapies.
Main Methods:
- Literature review of current clinical practice and research regarding surgical management of mRCC.
- Analysis of treatment strategies involving surgery, immunotherapy, and multimodal approaches.
Main Results:
- Surgery may be indicated for palliation of symptoms at primary or secondary sites.
- Cytoreductive surgery before immunotherapy may offer survival benefits in selected patients.
- Complete surgical excision of primary tumors and metastases can prolong survival, often with adjuvant immunotherapy.
Conclusions:
- The role of surgery in metastatic RCC is evolving, particularly with advancements in immunotherapy.
- Careful patient selection and consideration of less invasive therapies are essential.
- Further research, including randomized trials, is needed to define the optimal integration of surgery and immunotherapy.